Impact of European benefit-risk reassessment procedures on drug prescribing practices in Denmark

被引：0
|
作者：
Hallgreen, Christine E. [1 ]
Andersen, Morten [1 ]
De Bruin, Marie L. [1 ]
机构：
[1] Univ Copenhagen, Copenhagen, Denmark
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
965
引用
收藏
页码：468 / 469
页数：2
相关论文
共 50 条
  • [31] Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework
    van der Zanden, Tjitske M.
    Mooij, Miriam G.
    Vet, Nienke J.
    Neubert, Antje
    Rascher, Wolfgang
    Lagler, Florian B.
    Male, Christoph
    Grytli, Helene
    Halvorsen, Thomas
    de Hoog, Matthijs
    de Wildt, Saskia N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 952 - 965
  • [32] Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio
    Bernier, Marjorie
    Lancrerot, Sarah Line
    Parassol, Nadege
    Lavrut, Thibaud
    Viotti, Julien
    Rocher, Fanny
    Drici, Milou-Daniel
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 76 (04) : 472 - 477
  • [33] Key Changes in Benefit-Risk Assessment Guidelines and Implications for Data Analysis in Drug Development
    Hammad, Tarek A.
    Pinto, Cathy Anne
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (04): : 366 - 372
  • [34] Looking beyond borders: Integrating best practices in benefit-risk analysis into the field of Food and Nutrition
    Tijhuis, M. J.
    Pohjola, M. V.
    Gunnlaugsdottir, H.
    Kalogeras, N.
    Leino, O.
    Luteijn, J. M.
    Magnusson, S. H.
    Odekerken-Schroder, G.
    Poto, M.
    Tuomisto, J. T.
    Ueland, O.
    White, B. C.
    Holm, F.
    Verhagen, H.
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2012, 50 (01) : 77 - 93
  • [35] The impact of European regulatory policies on psychotropic drug prescribing patterns
    Garattini, S
    Bertele', V
    [J]. INTERNATIONAL REVIEW OF PSYCHIATRY, 2005, 17 (03) : 199 - 204
  • [36] Quantitative Drug Safety and Benefit-Risk Evaluation: Practical and Cross-Disciplinary Approaches
    Wang, Huan
    [J]. AMERICAN STATISTICIAN, 2023, 77 (01): : 111 - 112
  • [37] Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective
    Muehlbacher, Axel C.
    Juhnke, Christin
    Beyer, Andrea R.
    Garner, Sarah
    [J]. VALUE IN HEALTH, 2016, 19 (06) : 734 - 740
  • [38] Patient representatives' contributions to the benefit-risk assessment tasks of the European Medicines Agency scientific committees
    Bernabe, Rosemarie D. L. C.
    van Thiel, Ghislaine J. M. W.
    van Delden, Johannes
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (06) : 1248 - 1256
  • [39] The Impact of Uncertain Causality on Benefit-Risk Assessment: Insights from a Hierarchical Complexity Model
    Caster, O.
    [J]. DRUG SAFETY, 2012, 35 (10) : 919 - 919
  • [40] The impact of gabapentinoid and opioid prescribing practices on drug deaths: an epidemiological perspective
    Hebert, Harry L.
    Colvin, Lesley A.
    Smith, Blair H.
    [J]. PAIN MANAGEMENT, 2022, 12 (04) : 397 - 400
12345